Clinical Trial Update: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating crovalimab for pediatric atypical hemolytic uremic syndrome; status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• Crovalimab (crovalimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Atypical Hemolytic Uremic Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING